drugset

drugset / Trial / NCT06922539

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

NCT06922539 ↗

Phase 1 Recruiting 44 enrolled SciTech Development, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

Timeline

Start: 2025-12-11
Primary completion: 2027-05-01
Completion: 2028-10-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	fenretinide	Small molecule	—	Intravenous

Indications